A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial by Burnett, A, Hills, R, Nielsen, O, Freeman, S, Ali, A, Cahalin, P, Hunter, A, Thomas, I, Russell, N

The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial by Burnett, AK, Gupta, ED, Knapper, S, Khwaja, A, Sweeney, M, Kjeldsen, L, Hawkins, T, Betteridge, SE, Cahalin, P, Clark, RE, Hills, RK, Russell, NH

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia by Burnett, A, Russell, N, Hills, R, Kell, J, Nielsen, O, Dennis, M, Cahalin, P, Pocock, C, Ali, S, Burns, S, Freeman, S, Milligan, D, Clark, R, behalf of the UK NCRI AML Study Group

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. by Quek, L, Otto, G, Garnett, C, Lhermitte, L, Karamitros, D, Stoilova, B, Lau, I, Doondeea, J, Usukhbayar, B, Kennedy, A, Metzner, M, Goardon, N, Ivey, A, Allen, C, Gale, R, Davies, B, Sternberg, A, Killick, S, Hunter, H, Cahalin, P, Price, A, Carr, A, Griffiths, M, Virgo, P, Mackinnon, S, Grimwade, D, Freeman, S, Russell, N, Craddock, C, Mead, A, Peniket, A, Porcher, C, Vyas, P